American Journal of Kidney Diseases

Journal

Publication Venue For

  • Racial and Ethnic Disparities in Acute Care Utilization Among Patients With Glomerular Disease.  81:318-328.e1. 2023
  • Risk Factors for Incident CKD in Black and White Americans: The REGARDS Study. 2023
  • Age of Onset and Disease Course in Biopsy-Proven Minimal Change Disease: An Analysis From the Cure Glomerulonephropathy Network 2023
  • Blood Pressure Classification Status in Children With CKD Following Adoption of the 2017 American Academy of Pediatrics Guideline 2023
  • A Klotho-Derived Peptide as a Possible Novel Drug to Prevent Kidney Fibrosis.  80:285-288. 2022
  • Self-reported Race, Serum Creatinine, Cystatin C, and GFR in Children and Young Adults With Pediatric Kidney Diseases: A Report From the Chronic Kidney Disease in Children (CKiD) Study.  80:174-185.e1. 2022
  • Dialysis Nonadherence and Kidney Transplant Outcomes: A Retrospective Cohort Study.  80:46-54. 2022
  • Associations of Plasma Biomarkers of Inflammation, Fibrosis, and Kidney Tubular Injury With Progression of Diabetic Kidney Disease: A Cohort Study.  79:849-857.e1. 2022
  • Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.  79:677-687.e1. 2022
  • Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study.  79:404-416.e1. 2022
  • The Impact of COVID-19 on Nephrology Fellows—A Perspective From the 2020-2021 AJKD Editorial Intern Class.  78:769-771. 2021
  • Assessing the Relationship Between Serum Urate and Urolithiasis Using Mendelian Randomization: An Analysis of the UK Biobank.  78:210-218. 2021
  • Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood Pressure Intervention Trial).  78:48-56. 2021
  • Neighborhood Socioeconomic Status and Identification of Patients With CKD Using Electronic Health Records.  78:57-65.e1. 2021
  • Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy.  78:151-153. 2021
  • KDOQI US Commentary on the 2020 KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.  77:833-856. 2021
  • The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study.  77:490-499.e1. 2021
  • Burden and Cost of Caring for US Veterans With CKD: Initial Findings From the VA Renal Information System (VA-REINS).  77:397-405. 2021
  • Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States.  77:190-203.e1. 2021
  • KDOQI US Commentary on the 2020 ISPD Practice Recommendations for Prescribing High-Quality Goal-Directed Peritoneal Dialysis.  77:157-171. 2021
  • State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.  77:132-141. 2021
  • Telehealth for Home Dialysis in COVID-19 and Beyond: A Perspective From the American Society of Nephrology COVID-19 Home Dialysis Subcommittee.  77:142-148. 2021
  • CKD Management in Primary Care: Supporting Systems Change.  76:613-615. 2020
  • Impact of ABO-Incompatible Living Donor Kidney Transplantation on Patient Survival.  76:616-623. 2020
  • The New Age of Vascular Access: Choosing the Right Access for the Right Reason in Older Hemodialysis Patients.  76:457-459. 2020
  • KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update.  75:S1-S164. 2020
  • Donor-Recipient Relationship and Risk of ESKD in Live Kidney Donors of Varied Racial Groups.  75:333-341. 2020
  • APOL1 Nephropathy Risk Alleles and Mortality in African American Adults: A Cohort Study.  75:54-60. 2020
  • A Quality Improvement Initiative Targeting CRRT Delivered Dose: The What, the How, and the Why.  74:721-723. 2019
  • Second-Chance Placement of Hemodialysis Patients After Involuntary Discharge for Disruptive Behavior.  74:544-548. 2019
  • Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus–Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.  73:815-826. 2019
  • Quantification of Complications of Tunneled Hemodialysis Catheters.  73:462-464. 2019
  • Exploring Barriers and Potential Solutions in Home Dialysis: An NKF-KDOQI Conference Outcomes Report.  73:363-371. 2019
  • CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.  73:218-229. 2019
  • Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.  73:206-217. 2019
  • Albuminuria and Allograft Failure, Cardiovascular Disease Events, and All-Cause Death in Stable Kidney Transplant Recipients: A Cohort Analysis of the FAVORIT Trial.  73:51-61. 2019
  • The Role of Vitamin D in CKD Stages 3 to 4: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.  72:834-845. 2018
  • Tradeoffs in Vascular Access Selection in Elderly Patients Initiating Hemodialysis With a Catheter.  72:509-518. 2018
  • Serum Calcitriol Concentrations and Kidney Function Decline, Heart Failure, and Mortality in Elderly Community-Living Adults: The Health, Aging, and Body Composition Study.  72:419-428. 2018
  • Changes in Blood Pressure During Young Adulthood and Subsequent Kidney Function Decline: Findings From the Coronary Artery Risk Development in Young Adulthood (CARDIA) Study.  72:243-250. 2018
  • Urinary Biomarkers of Kidney Tubular Damage and Risk of Cardiovascular Disease and Mortality in Elders.  72:205-213. 2018
  • In Reply to ‘Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline’.  72:155. 2018
  • Medicare Costs Associated With Arteriovenous Fistulas Among US Hemodialysis Patients.  72:10-18. 2018
  • Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.  71:851-865. 2018
  • Evaluation of Kidney Donors: Core Curriculum 2018.  71:737-747. 2018
  • Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: A Multicenter Prospective Cohort Study.  71:677-689. 2018
  • Report of the Standardized Outcomes in Nephrology–Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access.  71:690-700. 2018
  • Lessons From International Differences in Vascular Access Practices and Outcomes.  71:452-454. 2018
  • Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).  71:352-361. 2018
  • Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review.  71:382-391. 2018
  • Association Between Gestational Diabetes and Incident Maternal CKD: The Coronary Artery Risk Development in Young Adults (CARDIA) Study.  71:112-122. 2018
  • KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD).  70:737-751. 2017
  • Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).  70:357-367. 2017
  • Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort.  70:377-385. 2017
  • Measures of Kidney Disease and the Risk of Venous Thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study.  70:182-190. 2017
  • Genetics of Blood Pressure: New Insights Into a Complex Trait.  69:723-725. 2017
  • Heme Oxygenase 1 as a Therapeutic Target in Acute Kidney Injury.  69:531-545. 2017
  • Performance of the CKD-EPI Equation to Estimate GFR in a Longitudinal Study of Autosomal Dominant Polycystic Kidney Disease.  69:482-484. 2017
  • Quiz: Acute Kidney Injury and Pancytopenia 5 Months After Kidney Transplantation.  69:A14-A17. 2017
  • Central Venous Occlusion in the Hemodialysis Patient.  68:803-807. 2016
  • Waist Circumference, Body Mass Index, and ESRD in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study.  67:62-69. 2016
  • A meta-analysis of the association of estimated GFR, albuminuria, diabetes mellitus, and hypertension with acute kidney injury.  66:602-612. 2015
  • Preoperative arterial microcalcification and clinical outcomes of arteriovenous fistulas for hemodialysis.  66:84-90. 2015
  • Influence of Kidney Function on Risk of Supratherapeutic International Normalized Ratio-Related Hemorrhage in Warfarin Users: A Prospective Cohort Study.  65:701-709. 2015
  • Association of high-sensitivity cardiac troponin t and natriuretic peptide with incident ESRD: The atherosclerosis risk in communities (ARIC) study.  65:550-558. 2015
  • KDOQI US commentary on the 2013 KDIGO clinical practice guideline for lipid management in CKD.  65:354-366. 2015
  • Validation study of medicare claims to identify older US adults with CKD using the reasons for geographic and racial differences in stroke (REGARDS) study.  65:249-258. 2015
  • Community mobility among older adults with reduced kidney function: A study of life-space.  63:429-436. 2014
  • Body mass index and early kidney function decline in young adults: A longitudinal analysis of the CARDIA (coronary artery risk development in young adults) study.  63:590-597. 2014
  • Chlorthalidone versus hydrochlorothiazide in hypertension treatment: Do we have the evidence to decide?.  63:387-389. 2014
  • Dietary patterns and risk of death and progression to ESRD in individuals with CKD: A cohort study.  64:204-213. 2014
  • Estimated GFR and risk of hip fracture in older men: Comparison of associations using cystatin C and creatinine.  63:31-39. 2014
  • Incident ESRD and treatment-resistant hypertension: The reasons for geographic and racial differences in stroke (REGARDS) study.  63:781-788. 2014
  • Is there a role for detection of complement-binding antibodies in kidney transplantation?.  63:558-560. 2014
  • Lipid-lowering guidelines and statin use in CKD: A time for change.  63:736-738. 2014
  • Objectives and design of the hemodialysis fistula maturation study.  63:104-112. 2014
  • Correlation of pre-existing vascular pathology with arteriovenous graft outcomes in hemodialysis patients.  62:1122-1129. 2013
  • Renovascular hypertension associated with pseudoaneurysm following blunt trauma.  62:839-843. 2013
  • Predialysis vascular access surgery in patients with failing kidney transplants.  62:398-400. 2013
  • Trajectories of kidney function decline in young black and white adults with preserved GFR: Results from the coronary artery risk development in young adults (CARDIA) study.  62:261-266. 2013
  • Dasatinib-induced nephrotic-range proteinuria.  61:1026-1031. 2013
  • α-Klotho and kidney function decline: An important step forward in understanding the link between mineral metabolism and kidney disease progression.  61:855-857. 2013
  • Relationships between serum and urine phosphorus with all-cause and cardiovascular mortality: The osteoporotic fractures in men (MrOS) study.  61:555-563. 2013
  • Geographic variation in CKD prevalence and ESRD incidence in the united states: Results from the reasons for geographic and racial differences in stroke (REGARDS) study.  61:395-403. 2013
  • Influence of kidney function on risk of hemorrhage among patients taking warfarin: A cohort study.  61:354-357. 2013
  • Pathologic femur fracture due to a brown tumor in a patient with secondary hyperparathyroidism and vitamin D-resistant rickets.  61:337-341. 2013
  • A man with acute kidney injury and cutaneous purpura.  62. 2013
  • Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD.  61:67-73. 2013
  • KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury.  61:649-672. 2013
  • KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD.  62:201-213. 2013
  • Screening strategies for tuberculosis in children with kidney disease: What is cost-effective?.  61:3-5. 2013
  • Association of hemodialysis central venous catheter use with ipsilateral arteriovenous vascular access survival.  60:983-989. 2012
  • Low income and albuminuria among REGARDS (Reasons for geographic and racial differences in stroke) study participants.  60:779-786. 2012
  • Predicting successful arteriovenous fistula creation.  60:498. 2012
  • Kidney disease education one year after the medicare improvement of patients and providers act: A survey of US nephrology practices.  59:892-894. 2012
  • Regional citrate anticoagulation for continuous renal replacement therapy: The better alternative?.  59:745-747. 2012
  • Association of factor V gene polymorphism with arteriovenous graft failure.  59:682-688. 2012
  • Comparison of concurrent complications of CKD by 2 risk categorization systems.  59:372-381. 2012
  • Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy.  59:210-221. 2012
  • Association of family history of ESRD, prevalent albuminuria, and reduced GFR with incident esrd.  59:25-31. 2012
  • Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis.  59:122-125. 2012
  • Peripherally inserted central catheters and other intravascular devices: How safe are they for hemodialysis patients?.  60:510-513. 2012
  • Albuminuria, kidney function, and the incidence of cognitive impairment among adults in the United States.  58:756-763. 2011
  • Medial fibrosis, vascular calcification, intimal hyperplasia, and arteriovenous fistula maturation.  58:437-443. 2011
  • Arteriovenous graft placement in predialysis patients: A potential catheter-sparing strategy.  58:243-247. 2011
  • Association of waist circumference and body mass index with all-cause mortality in CKD: The REGARDS (Reasons for Geographic and Racial Differences in Stroke) study.  58:177-185. 2011
  • Development and validation of a self-assessment tool for albuminuria: Results from the reasons for geographic and racial differences in stroke (REGARDS) study.  58:196-205. 2011
  • Fistula first: Recent progress and ongoing challenges.  57:3-6. 2011
  • Improving incident fistula rates: A process of care issue.  57:814-817. 2011
  • Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.  56:1108-1116. 2010
  • Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons.  56:872-882. 2010
  • Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study.  56:861-871. 2010
  • Warfarin dosing in patients with impaired kidney function.  56:823-831. 2010
  • A physiologic-based approach to the treatment of acute hyperkalemia.  56:578-584. 2010
  • Low medication adherence and hypertension control among adults with CKD: Data from the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study.  56:447-457. 2010
  • Practical Vancomycin Dosing in Hemodialysis Patients in the Era of Emerging Vancomycin Resistance: A Single-Center Experience.  55:1163-1165. 2010
  • Hypertension Awareness, Treatment, and Control in Adults With CKD: Results From the Chronic Renal Insufficiency Cohort (CRIC) Study.  55:441-451. 2010
  • Cryoglobulinemic Glomerulopathy Complicating Helicobacter pylori-Associated Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.  54:770-774. 2009
  • Treatment Guidelines for Dialysis Catheter-Related Bacteremia: An Update.  54:13-17. 2009
  • Treatment of Dialysis Catheter-Related Enterococcus Bacteremia With an Antibiotic Lock: A Quality Improvement Report.  53:107-111. 2009
  • Management of Hyperuricemia and Gout in CKD.  52:994-1009. 2008
  • Kidney Function and Cognitive Impairment in US Adults: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study.  52:227-234. 2008
  • Racial Differences in the Competing Risks of Mortality and ESRD After Acute Myocardial Infarction.  52:251-261. 2008
  • In Reply.  52:198. 2008
  • Metabolic Syndrome, Proteinuria, and the Risk of Progressive CKD in Hypertensive African Americans.  51:732-740. 2008
  • Prophylaxis Against Dialysis Catheter-Related Bacteremia: A Glimmer of Hope.  51:165-168. 2008
  • Vascular Access: Core Curriculum 2008.  51:702-708. 2008
  • In Reply.  50:1052. 2007
  • Treatment of Dialysis Catheter-Related Staphylococcus aureus Bacteremia With an Antibiotic Lock: A Quality Improvement Report.  50:289-295. 2007
  • Improving Outcomes From Acute Kidney Injury: Report of an Initiative.  50:1-4. 2007
  • Arteriovenous Grafts Still Have a Place in Dialysis.  49:873-874. 2007
  • Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial.  48:739-751. 2006
  • In Reply.  48:181-182. 2006
  • Citrate-Based Replacement Solutions with Continuous Venovenous Hemofiltration: Not as Simple as It Sounds.  47:1086. 2006
  • Needle Infiltration of Arteriovenous Fistulae in Hemodialysis: Risk Factors and Consequences.  47:1020-1026. 2006
  • Effect of change in vascular access on patient mortality in hemodialysis patients.  47:469-477. 2006
  • Current and evolving immunosuppressive regimens in kidney transplantation.  47. 2006
  • Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: The Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP).  46:1058-1064. 2005
  • Delay in time to receipt of thrombolytic medication among medicare patients with kidney disease.  46:595-602. 2005
  • K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease: Work group membership.  46. 2005
  • Tunneled catheters in hemodialysis patients: Reasons and subsequent outcomes.  46:501-508. 2005
  • Renal replacement therapies for acute renal failure: Does dose matter?.  45:1139-1143. 2005
  • Hepatitis C infection is acquired pre-ESRD.  45:684-689. 2005
  • Shorter unassisted patency of vascular access after angioplasty in women [1] (multiple letters).  46:167. 2005
  • Dialysis catheter-related bacteremia: Treatment and prophylaxis.  44:779-791. 2004
  • Vascular access stenosis: Comparison of arteriovenous grafts and fistulas.  44:859-865. 2004
  • Associations with predialysis vascular access management.  43:1008-1013. 2004
  • Hypertension..  44:369-375. 2004
  • Medullary cystic kidney disease type 2 [1] (multiple letters).  43:1142-1143. 2004
  • Transplantation in the diabetic patient with advanced chronic kidney disease: A task force report.  44:529-542. 2004
  • Interventional nephrology: Work in progress.  42:388-391. 2003
  • Chronic use of sodium ferric gluconate complex in hemodialysis patients: Safety of higher-dose (≥250 mg) administration.  41:651-657. 2003
  • Cystic and Inherited Kidney Diseases.  42:1305-1317. 2003
  • K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification.  39. 2002
  • Maintenance immunosuppression in the renal transplant recipient: an overview..  38:S25-S35. 2001
  • Clinical consequences of infected arteriovenous grafts in hemodialysis patients.  38:975-978. 2001
  • Evolution of immunosuppression and continued importance of acute rejection in renal transplantation.  38. 2001
  • Maintenance immunosuppression in the renal transplant recipient: An overview.  38. 2001
  • Mitochondrial DNA mutations in black Americans with hypertension-associated end-stage renal disease.  38:529-536. 2001
  • Predictors of arteriovenous graft patency after radiologic intervention in hemodialysis patients.  37:945-953. 2001
  • IgA1 glycosylation and the pathogenesis of IgA nephropathy.  35:551-554. 2000
  • Is there a role for Chlamydia pneumoniae in hemodialysis vascular access thrombosis?.  36:1122-1125. 2000
  • Natural history of arteriovenous grafts in hemodialysis patients.  36:68-74. 2000
  • Mycophenolate mofetil in cadaveric renal transplantation.  34:296-303. 1999
  • T594M mutation in the ENaC β subunit and low-renin hypertension in blacks.  34:579-583. 1999
  • Homocysteine, b vitamins, and vascular-access thrombosis in patients treated with hemodialysis.  32:475-481. 1998
  • Oxygen free radicals and contrast nephropathy.  32:64-71. 1998
  • Prospective evaluation of an anemia treatment algorithm in hemodialysis patients.  32:635-641. 1998
  • Acute renal failure in the 21st century: Recommendations for management and outcomes assessment.  29:793-799. 1997
  • The impact of renal transplantation on survival in hepatitis C- positive end-stage renal disease patients.  29:608-614. 1997
  • Benefits of continued cyclosporine through an indigent drug program.  28:572-577. 1996
  • Dilemmas in renal transplantation: When the clinical course and histological findings differ.  27:435-440. 1996
  • Effect of bicarbonate administration on plasma potassium in dialysis patients: Interactions with insulin and albuterol.  28:508-514. 1996
  • Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease.  27:341-346. 1996
  • Postdialysis fatigue.  28:732-736. 1996
  • Salt-sensitive hypertension: Lessons from animal models.  28:775-782. 1996
  • Effect of albuterol treatment on subsequent dialytic potassium removal.  26:607-613. 1995
  • Liddle's syndrome: A public health menace?.  25:924-927. 1995
  • Rapid renal deterioration secondary to oxalate in a patient with diabetic gastroenteropathy.  26:68-71. 1995
  • Development of Bacterial Biofilms on Silastic Catheter Materials in Peritoneal Dialysis Fluid.  23:709-716. 1994
  • Posttransplant Erythrocytosis: An Enigma Revisited.  24:1-11. 1994
  • Immunoglobulin A-Fibronectin Aggregate Levels in Children and Adults With Immunoglobulin A Nephropathy.  22:1-4. 1993
  • Reply.  21:344. 1993
  • Tapering or Discontinuing Cyclosporine for Financial Reasons—A Single-Center Experience.  21:9-15. 1993
  • Extrarenal potassium tolerance in chronic renal failure: implications for the treatment of acute hyperkalemia..  19. 1992
  • Correspondence.  19:391. 1992
  • Cytokine-Induced Immunoglobulin Production in Primary IgA Nephropathy.  20:611-617. 1992
  • Familial IgA Nephropathy Associated With Bilateral Sensorineural Deafness.  19:592-596. 1992
  • Musculoskeletal Complications After Renal Transplantation: Pathogenesis and Treatment.  19:99-120. 1992
  • Reply.  20:531. 1992
  • US Minority Groups and End-Stage Renal Disease: A Disproportionate Share.  19:411-413. 1992
  • Changing Patterns of End-Stage Renal Disease Due to Hypertension.  18:336-343. 1991
  • Epstein-Barr virus Transformation of B Lymphocytes From IgA Nephropathy Patients and First-Degree Relatives Results in Increased Immunoglobulin Synthesis not Restricted to IgA.  17:55-61. 1991
  • Long-Term Follow-Up of a Human Subject With a Remnant Kidney.  18:509-513. 1991
  • Macroscopic Hematuria and Proteinuria Preceding Renal IgA Deposition in Patients With IgA Nephropathy.  17:472-479. 1991
  • Selective Elevation of Monomeric IgA1 in IgA Nephropathy Patients With Normal Renal Function.  18:313-319. 1991
  • C4B Deficiency in Two Siblings With IgA Nephropathy.  15:66-71. 1990
  • Evaluation of Renal Transplant Dysfunction by Duplex Doppler Sonography: A Prospective Study and Review of the Literature.  15:544-550. 1990
  • Tubulointerstitial Nephritis Due to Vancomycin.  14:512-515. 1989
  • Immunobiology of IgA..  12:378-383. 1988
  • A Comparison of OKT3 Monoclonal Antibody and Corticosteroids in the Treatment of Acute Renal Allograft Rejection.  11:86-89. 1988
  • Activation of Complement in IgA Nephropathy.  12:437-442. 1988
  • Cell Surface Receptors for Kidney Basement Membranes.  12:78-83. 1988
  • Familial Clustering and Immunogenetic Aspects of IgA Nephropathy.  12:366-370. 1988
  • Hyperphosphatemia, Hypocalcemia, and Renal Failure in a Patient With Acute Leukemia.  11:442-445. 1988
  • Immunobiology of IgA.  12:378-383. 1988
  • Results of Coronary Artery Bypass Grafting in End-Stage Renal Disease.  12:266-270. 1988
  • Cat-Bite Peritonitis: Pasteurella Multocida Peritonitis Following Feline Contamination of Peritoneal Dialysis Tubing.  10:318-319. 1987
  • Oxalosis in Bone Causing a Radiographical Mimicry of Renal Osteodystrophy.  9:436-440. 1987
  • Renal Disease and Syphilis: A Report of Nephrotic Syndrome With Minimal Change Disease.  9:176-179. 1987
  • Striking Elevation of Serum IgA, IgA-Containing Immune Complexes, and IgA Rheumatoid Factor in Clinically Silent Dermatitis Herpetiformis.  10:378-384. 1987
  • Treatment of Uremic Pericarditis and Pericardial Effusion.  10:2-8. 1987
  • Focal Sclerosis of Hypertrophied Glomeruli in Solitary Functioning Kidneys of Humans.  5:226-232. 1985
  • Hemodialysis Without Anticoagulation.  5:32-35. 1985
  • Staphylococcus Aureus Bacteremia in Patients on Chronic Hemodialysis.  6:412-419. 1985
  • IgA Nephropathy: Presentation, Clinical Course, and Prognosis in Children and Adults.  4:192-200. 1984
  • International Standard Serial Number (issn)

  • 0272-6386
  • Electronic International Standard Serial Number (eissn)

  • 1523-6838